ETRA: Electra Therapeutics prices upsized $350M IPO at $15 — Nasdaq debut tape
Posted: Fri Sep 18, 2026 2:48 pm
Fresh immunology IPO into a post-Fed / witching Friday — opening-print liquidity risk first.
GlobeNewswire (18 Sep): Electra Therapeutics priced an upsized IPO of 23,333,334 shares at $15 (midpoint of $14–$16 marketed range) for ~$350M gross. Shares listed Nasdaq Global Select as ETRA; offering expected to close ~21 Sep. OrbiMed-backed clinical-stage immunology name — treat day-one tape as float discovery, not a fundamentals vote.
Scalper read: IPOs on a quiet macro Friday can whip on thin float and syndicate overhang. Watch opening range vs. $15 print for fade/reclaim; don’t chase the first green tick without a liquidity plan. Pair context vs. other recent biotech debuts, not Mag7 beta.
Source (fair paraphrase): Electra / GlobeNewswire 18 Sep 2026 — https://www.globenewswire.com/news-rele ... ering.html
Fading first-hour IPO premium into the $15 print, or waiting for a failed reclaim?
Anyone seeing real size in ETRA vs. typical biotech debut churn?
GlobeNewswire (18 Sep): Electra Therapeutics priced an upsized IPO of 23,333,334 shares at $15 (midpoint of $14–$16 marketed range) for ~$350M gross. Shares listed Nasdaq Global Select as ETRA; offering expected to close ~21 Sep. OrbiMed-backed clinical-stage immunology name — treat day-one tape as float discovery, not a fundamentals vote.
Scalper read: IPOs on a quiet macro Friday can whip on thin float and syndicate overhang. Watch opening range vs. $15 print for fade/reclaim; don’t chase the first green tick without a liquidity plan. Pair context vs. other recent biotech debuts, not Mag7 beta.
Source (fair paraphrase): Electra / GlobeNewswire 18 Sep 2026 — https://www.globenewswire.com/news-rele ... ering.html
Fading first-hour IPO premium into the $15 print, or waiting for a failed reclaim?
Anyone seeing real size in ETRA vs. typical biotech debut churn?